PMID- 27282261
OWN - NLM
STAT- MEDLINE
DCOM- 20170801
LR  - 20220310
IS  - 2005-1212 (Electronic)
IS  - 1976-2283 (Print)
IS  - 1976-2283 (Linking)
VI  - 10
IP  - 6
DP  - 2016 Nov 15
TI  - Limited Effect of Rebamipide in Addition to Proton Pump Inhibitor (PPI) in the 
      Treatment of Post-Endoscopic Submucosal Dissection Gastric Ulcers: A Randomized 
      Controlled Trial Comparing PPI Plus Rebamipide Combination Therapy with PPI 
      Monotherapy.
PG  - 917-924
LID - 10.5009/gnl15486 [doi]
AB  - BACKGROUND/AIMS: The ability of endoscopic submucosal dissection (ESD) to resect 
      large early gastric cancers (EGCs) results in the need to treat large artificial 
      gastric ulcers. This study assessed whether the combination therapy of rebamipide 
      plus a proton pump inhibitor (PPI) offered benefits over PPI monotherapy. 
      METHODS: In this prospective, randomized, multicenter, open-label, and 
      comparative study, patients who had undergone ESD for EGC or gastric adenoma were 
      randomized into groups receiving either rabeprazole monotherapy (10 mg/day, n=64) 
      or a combination of rabeprazole plus rebamipide (300 mg/day, n=66). The Scar 
      stage (S stage) ratio after treatment was compared, and factors independently 
      associated with ulcer healing were identified by using multivariate analyses. 
      RESULTS: The S stage rates at 4 and 8 weeks were similar in the two groups, even 
      in the subgroups of patients with large amounts of tissue resected and regardless 
      of CYP2C19 genotype. Independent factors for ulcer healing were circumferential 
      location of the tumor and resected tissue size; the type of treatment did not 
      affect ulcer healing. CONCLUSIONS: Combination therapy with rebamipide and PPI 
      had limited benefits compared with PPI monotherapy in the treatment of post-ESD 
      gastric ulcer (UMIN Clinical Trials Registry, UMIN000007435).
FAU - Nakamura, Kazuhiko
AU  - Nakamura K
AD  - Department of Medicine and Bioregulatory Science, Graduate School of Medical 
      Sciences, Kyushu University, Fukuoka, Japan.
FAU - Ihara, Eikichi
AU  - Ihara E
AD  - Department of Medicine and Bioregulatory Science, Graduate School of Medical 
      Sciences, Kyushu University, Fukuoka, Japan.
FAU - Akiho, Hirotada
AU  - Akiho H
AD  - Department of Gastroenterology, Kitakyushu Municipal Medical Center, Kitakyushu, 
      Japan.
FAU - Akahoshi, Kazuya
AU  - Akahoshi K
AD  - Department of Gastroenterology, Aso Iizuka Hospital, Iizuka, Japan.
FAU - Harada, Naohiko
AU  - Harada N
AD  - Department of Gastroenterology, National Hospital Organization Kyushu Medical 
      Center, Fukuoka, Japan.
FAU - Ochiai, Toshiaki
AU  - Ochiai T
AD  - Division of Gastroenterology, Saiseikai Fukuoka General Hospital, Fukuoka, Japan.
FAU - Nakamura, Norimoto
AU  - Nakamura N
AD  - Department of Gastroenterology, Harasanshin Hospital, Fukuoka, Japan.
FAU - Ogino, Haruei
AU  - Ogino H
AD  - Department of Medicine and Bioregulatory Science, Graduate School of Medical 
      Sciences, Kyushu University, Fukuoka, Japan.
AD  - Department of Gastroenterology, Kitakyushu Municipal Medical Center, Kitakyushu, 
      Japan.
FAU - Iwasa, Tsutomu
AU  - Iwasa T
AD  - Department of Medicine and Bioregulatory Science, Graduate School of Medical 
      Sciences, Kyushu University, Fukuoka, Japan.
FAU - Aso, Akira
AU  - Aso A
AD  - Department of Medicine and Bioregulatory Science, Graduate School of Medical 
      Sciences, Kyushu University, Fukuoka, Japan.
FAU - Iboshi, Yoichiro
AU  - Iboshi Y
AD  - Department of Medicine and Bioregulatory Science, Graduate School of Medical 
      Sciences, Kyushu University, Fukuoka, Japan.
FAU - Takayanagi, Ryoichi
AU  - Takayanagi R
AD  - Department of Medicine and Bioregulatory Science, Graduate School of Medical 
      Sciences, Kyushu University, Fukuoka, Japan.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - Korea (South)
TA  - Gut Liver
JT  - Gut and liver
JID - 101316452
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (Quinolones)
RN  - 32828355LL (Rabeprazole)
RN  - LR583V32ZR (rebamipide)
RN  - OF5P57N2ZX (Alanine)
SB  - IM
MH  - Adenoma/surgery
MH  - Aged
MH  - Alanine/administration & dosage/*analogs & derivatives
MH  - Anti-Ulcer Agents/*administration & dosage
MH  - Drug Therapy, Combination
MH  - Endoscopic Mucosal Resection/adverse effects
MH  - Female
MH  - Gastric Mucosa/surgery
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/*drug therapy/etiology
MH  - Prospective Studies
MH  - Proton Pump Inhibitors/*administration & dosage
MH  - Quinolones/*administration & dosage
MH  - Rabeprazole/*administration & dosage
MH  - Stomach Neoplasms/surgery
MH  - Stomach Ulcer/*drug therapy/etiology
MH  - Treatment Outcome
PMC - PMC5087931
OTO - NOTNLM
OT  - Antiulcer agents
OT  - Endoscopy
OT  - Proton pump inhibitors
OT  - Stomach ulcer
OT  - Therapeutics
EDAT- 2016/10/28 06:00
MHDA- 2017/08/02 06:00
PMCR- 2016/11/01
CRDT- 2016/06/11 06:00
PHST- 2015/09/24 00:00 [received]
PHST- 2015/12/14 00:00 [revised]
PHST- 2016/01/13 00:00 [accepted]
PHST- 2016/10/28 06:00 [pubmed]
PHST- 2017/08/02 06:00 [medline]
PHST- 2016/06/11 06:00 [entrez]
PHST- 2016/11/01 00:00 [pmc-release]
AID - gnl15486 [pii]
AID - gnl-10-917 [pii]
AID - 10.5009/gnl15486 [doi]
PST - ppublish
SO  - Gut Liver. 2016 Nov 15;10(6):917-924. doi: 10.5009/gnl15486.